

KURZPROTOKOLL
EsPhALL2017

Öffentlicher Titel	Phase III Studie zu Imatinib + Chemotherapie bei Philadelphia-positiver ALL
Wissenschaftl. Titel	International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Kurztitel	EsPhALL2017
Studienart	prospektiv, Therapiestudie, randomisiert, offen/unverblindet, dreiarmlig, Investigator Initiated Trial (IIT)
Studienphase	Phase III
Erkrankung	Kinder: Leukämien und Lymphome: Neu diagnostiziert / de novo
Einschlusskriterien	<ul style="list-style-type: none">- Newly diagnosed de novo ALL (B-ALL or T-ALL) with definitive evidence of BCR-ABL1 fusion by karyotype, FISH and/or RT-PCR- Adequate liver, cardiac, renal function
Ausschlusskriterien	<ul style="list-style-type: none">- Known history of chronic myelogenous leukemia (CML)- ALL developing after a previous cancer treated with cytotoxic chemotherapy- Active, uncontrolled infection or active systemic illness that requires ongoing vasopressor support or mechanical ventilation- Down syndrome- Pregnancy and Breast Feeding- Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block- Prior treatment with dasatinib, or any BCR-ABL1 inhibitor other than imatinib.
Alter	1 - 20 Jahre
Molekularer Marker	BCR-ABL1
Prüfzentren	Universitätsklinikum Frankfurt (Aktiv) Klinik für Kinder- und Jugendmedizin Theodor-Stern-Kai 7 60590 Frankfurt am Main Prof. Dr. med. Thomas Lehrnbecher Tel: 069 6301-6489 Fax: 069 6301-6009 thomas.lehrnbecher@kgu.de
Sponsor	Università degli Studi Milano Bicocca